PMID- 25320259
OWN - NLM
STAT- MEDLINE
DCOM- 20150617
LR  - 20211021
IS  - 1757-790X (Electronic)
IS  - 1757-790X (Linking)
VI  - 2014
DP  - 2014 Oct 15
TI  - Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
LID - 10.1136/bcr-2014-206314 [doi]
LID - bcr2014206314
AB  - Although few recent studies have reported efficacy and safety data among patients 
      with multiple sclerosis (MS) switching between immunotherapies, data on the 
      mechanism of rebound activity postwithdrawal of fingolimod in patients with MS is 
      scarce. A 36-year-old woman developed severe reactivation of her disease within 
      7 weeks of fingolimod's withdrawal despite the absence of breakthrough disease 
      during the 8-week natalizumab washout period previously. The clinical 
      presentation and radiological features were described indicating the diagnostic 
      challenge given the potential risk of developing progressive multifocal 
      leucoencephalopathy. The severe reactivation postwithdrawal of fingolimod could 
      be due to the immune reconstitution inflammatory syndrome (IRIS) given the abrupt 
      rise in lymphocyte count. Patients who discontinued fingolimod might be at risk 
      of developing IRIS resulting in disease reactivation in the washout period.
CI  - 2014 BMJ Publishing Group Ltd.
FAU - Alroughani, R
AU  - Alroughani R
AUID- ORCID: 0000-0001-5436-5804
AD  - Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, 
      Kuwait Neurology Clinic, Dasman Diabetes Institute, Kuwait City, Kuwait.
FAU - Almulla, A
AU  - Almulla A
AD  - Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, 
      Kuwait.
FAU - Lamdhade, S
AU  - Lamdhade S
AD  - Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, 
      Kuwait.
FAU - Thussu, A
AU  - Thussu A
AD  - Division of Neurology, Department of Medicine, Amiri Hospital, Kuwait City, 
      Kuwait Neurology Clinic, Dasman Diabetes Institute, Kuwait City, Kuwait.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20141015
PL  - England
TA  - BMJ Case Rep
JT  - BMJ case reports
JID - 101526291
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Natalizumab)
RN  - 0 (Propylene Glycols)
RN  - G926EC510T (Fingolimod Hydrochloride)
RN  - NGZ37HRE42 (Sphingosine)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Drug Administration Schedule
MH  - Female
MH  - Fingolimod Hydrochloride
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*complications
MH  - Immunosuppressive Agents/adverse effects/*therapeutic use
MH  - Multiple Sclerosis/*drug therapy/*immunology
MH  - Natalizumab
MH  - Propylene Glycols/adverse effects/*therapeutic use
MH  - Recurrence
MH  - Sphingosine/adverse effects/*analogs & derivatives/therapeutic use
PMC - PMC4202063
EDAT- 2014/10/17 06:00
MHDA- 2015/06/18 06:00
PMCR- 2016/10/15
CRDT- 2014/10/17 06:00
PHST- 2014/10/17 06:00 [entrez]
PHST- 2014/10/17 06:00 [pubmed]
PHST- 2015/06/18 06:00 [medline]
PHST- 2016/10/15 00:00 [pmc-release]
AID - bcr-2014-206314 [pii]
AID - 10.1136/bcr-2014-206314 [doi]
PST - epublish
SO  - BMJ Case Rep. 2014 Oct 15;2014:bcr2014206314. doi: 10.1136/bcr-2014-206314.